Gregory Yost, DO
Cardiovascular Disease · Danville, PANPI 1558500280
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,792 of the $3,752 with a category attached, or 74.4%. Medtronic accounts for 81.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $1,750 and has fallen 91.4% since, to $150 in 2025.
Across 29 payments — averaging $129.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- AstraZeneca$336
- Heartflow, Inc.$150
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$100
- Boston Scientific$83
- Sanofi$23
Across 4 payments — averaging $5530.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shockwave Medical, Inc$22K
What the payments were for
- Travel & lodging$2,79274%
- Food & beverage$96026%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 20 | $3,060 |
| AstraZeneca | 4 | $336 |
| Heartflow, Inc. | 2 | $150 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $100 |
| Boston Scientific | 1 | $83 |
| Sanofi | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$124
How this compares
$3,752 in reported general payments places this provider in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 73 | $68,200 |
| Repatha SureclickEvolocumab | 45 | $24,053 |
| JardianceEmpagliflozin | 21 | $20,662 |
| EntrestoSacubitril/Valsartan | 15 | $17,275 |
| XareltoRivaroxaban | 14 | $14,023 |
| Metoprolol Succinate | 147 | $2,840 |
| Atorvastatin Calcium | 158 | $2,360 |
| Ezetimibe | 49 | $1,929 |
| ClopidogrelClopidogrel Bisulfate | 90 | $1,675 |
| Torsemide | 36 | $1,327 |
| Lisinopril | 103 | $776 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 37 | $742 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 20 | $727 |
| Amlodipine Besylate | 111 | $697 |
| Furosemide | 83 | $640 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Danville
- Dominik BeerDanville$87K
- Hemal GadaWormleysburg$1.8M
- Benjamin KalsmithPgh$1.7M
- Peter KoweyWynnewood$1.5M
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Rhian DaviesYork$853K
- Sarang MangalmurtiBryn Mawr$728K
- Sabahat BokhariAllentown$578K
- George GabrielPittsburgh$563K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.